Tags

Type your tag names separated by a space and hit enter

Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy.
Cardiovasc Ther. 2012 Apr; 30(2):61-74.CT

Abstract

AIMS

This post hoc analysis compared the effects of switching to ezetimibe/simvastatin 10/20 mg (EZE/SIMVA) or rosuvastatin 10 mg (ROSUVA) in uncontrolled high-risk hypercholesterolemic patients with/without type 2 diabetes mellitus (T2DM) despite statin monotherapy.

METHODS

Patients (n = 618) at high risk for coronary vascular disease with elevated LDL-C ≥100 and ≤190 mg/dL despite use of statins were randomized 1:1 to double-blind EZE/SIMVA 10/20 mg or ROSUVA 10 mg for 6 weeks. Patients were classified as having T2DM based on ≥1 of the following: diagnosis of T2DM, antidiabetic medication, or FPG ≥126 mg/dL. This analysis evaluated percent changes from baseline in lipids among patients with (n = 182) and without T2DM (n = 434).

RESULTS

EZE/SIMVA was more effective than ROSUVA at lowering LDL-C, TC, non-HDL-C, and apo B in the overall study population and within both subgroups. Numerically, greater between-treatment reductions in LDL-C, TC, non-HDL-C, and apo B were seen in patients with T2DM versus those without T2DM. A significant interaction (P= 0.015) was seen for LDL-C indicating that patients with T2DM achieved larger between-group reductions versus those without T2DM.

CONCLUSIONS

Switching to EZE/SIMVA 10/20 mg versus ROSUVA 10 mg provided superior lipid reductions in patients with/without T2DM.

Authors+Show Affiliations

3rd Department of Internal Medicine, Medical Faculty and University Hospital Olomouc, Olomouc, Czech Republic. helena.vaverkova@fnol.czNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20626402

Citation

Vaverkova, Helena, et al. "Lipid-altering Efficacy of Ezetimibe/simvastatin 10/20 Mg Compared to Rosuvastatin 10 Mg in High-risk Patients With and Without Type 2 Diabetes Mellitus Inadequately Controlled Despite Prior Statin Monotherapy." Cardiovascular Therapeutics, vol. 30, no. 2, 2012, pp. 61-74.
Vaverkova H, Farnier M, Averna M, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy. Cardiovasc Ther. 2012;30(2):61-74.
Vaverkova, H., Farnier, M., Averna, M., Missault, L., Viigimaa, M., Dong, Q., Shah, A., Johnson-Levonas, A. O., & Brudi, P. (2012). Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy. Cardiovascular Therapeutics, 30(2), 61-74. https://doi.org/10.1111/j.1755-5922.2010.00181.x
Vaverkova H, et al. Lipid-altering Efficacy of Ezetimibe/simvastatin 10/20 Mg Compared to Rosuvastatin 10 Mg in High-risk Patients With and Without Type 2 Diabetes Mellitus Inadequately Controlled Despite Prior Statin Monotherapy. Cardiovasc Ther. 2012;30(2):61-74. PubMed PMID: 20626402.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy. AU - Vaverkova,Helena, AU - Farnier,Michel, AU - Averna,Maurizio, AU - Missault,Luc, AU - Viigimaa,Margus, AU - Dong,Qian, AU - Shah,Arvind, AU - Johnson-Levonas,Amy O, AU - Brudi,Philippe, Y1 - 2010/07/07/ PY - 2010/7/15/entrez PY - 2010/7/16/pubmed PY - 2012/7/4/medline SP - 61 EP - 74 JF - Cardiovascular therapeutics JO - Cardiovasc Ther VL - 30 IS - 2 N2 - AIMS: This post hoc analysis compared the effects of switching to ezetimibe/simvastatin 10/20 mg (EZE/SIMVA) or rosuvastatin 10 mg (ROSUVA) in uncontrolled high-risk hypercholesterolemic patients with/without type 2 diabetes mellitus (T2DM) despite statin monotherapy. METHODS: Patients (n = 618) at high risk for coronary vascular disease with elevated LDL-C ≥100 and ≤190 mg/dL despite use of statins were randomized 1:1 to double-blind EZE/SIMVA 10/20 mg or ROSUVA 10 mg for 6 weeks. Patients were classified as having T2DM based on ≥1 of the following: diagnosis of T2DM, antidiabetic medication, or FPG ≥126 mg/dL. This analysis evaluated percent changes from baseline in lipids among patients with (n = 182) and without T2DM (n = 434). RESULTS: EZE/SIMVA was more effective than ROSUVA at lowering LDL-C, TC, non-HDL-C, and apo B in the overall study population and within both subgroups. Numerically, greater between-treatment reductions in LDL-C, TC, non-HDL-C, and apo B were seen in patients with T2DM versus those without T2DM. A significant interaction (P= 0.015) was seen for LDL-C indicating that patients with T2DM achieved larger between-group reductions versus those without T2DM. CONCLUSIONS: Switching to EZE/SIMVA 10/20 mg versus ROSUVA 10 mg provided superior lipid reductions in patients with/without T2DM. SN - 1755-5922 UR - https://www.unboundmedicine.com/medline/citation/20626402/Lipid_altering_efficacy_of_ezetimibe/simvastatin_10/20_mg_compared_to_rosuvastatin_10_mg_in_high_risk_patients_with_and_without_type_2_diabetes_mellitus_inadequately_controlled_despite_prior_statin_monotherapy_ L2 - https://doi.org/10.1111/j.1755-5922.2010.00181.x DB - PRIME DP - Unbound Medicine ER -